EUCTR2012-000996-17-IT进行中（未招募）不适用
Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life. - CABA-15
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA0 个研究点开始时间: 2012年8月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Diagnosis of histologically or cytologically proven prostate adenocarcinoma that is resistant to hormone therapy and previously treated with a docetaxel-containing regimen. 2. Age =18 years old. 3. Patient must have either radiologically measurable or non-measurable disease. 4. Received prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH) agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with estramustine, or other hormonal agents. 5. Life expectancy > 6 months. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 - 2 (ie, patient must be ambulatory, capable of all self-care, and up and about more than 50% of waking hours). 7. Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Previous treatment with cabazitaxel. 2. Prior isotope therapy or radiotherapy to = 30% of bone marrow. In case of prior isotope therapy 12 weeks must have elapsed prior to first study drug administration. 3. Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade > 1(National Cancer Institute Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization. 4. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study. 5. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which chemotherapy has been completed = 5 years ago and from which the patient has been disease-free for = 5 years. 6. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization. 7. Known brain or leptomeningeal involvement. 8. Other concurrent serious illness or medical conditions. 9. Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure or myocardial infarction within last 6 months is also not allowed. 10. Any severe acute or chronic medical condition which could impair the ability of the patient to participate to the study or to comply with the study procedures or interfere with interpretation of study results. 11. Absence of signed and dated Institutional Review Board (IRB)-approved patient informed consent form prior to enrollment into the study. 12. Patients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period. The definition of ''effective method of contraception'' will be based on the Investigator's judgment. Patients' Partners of childbearing potential (unless surgically sterile, post menopausal or for another reason have no chance of becoming pregnant) not protected by highly effective contraceptive method of birth control as defined for contraception in the Informed Consent Form and /or in a local protocol addendum. 13. Inadequate organ and bone marrow function. 14. Contraindications to the use of corticosteroid treatment. 15. Symptomatic peripheral neuropathy grade > 2 (National Cancer Institute Common Terminology Criteria [NCI CTCAE] v.4.03).
研究者
相似试验
进行中（未招募）
不适用
2nd line treatment with cabazitaxel in patients with NSCLCPatients with stage IIIB with pleural effusion or stage IV NSCLC with documented disease progression during or after completion of docetaxel-based treatment are eligible for the study.EUCTR2012-000275-16-GRHellenic Oncology Research Group (H.O.R.G.)
进行中（未招募）
1 期
A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet)breast or lung cancer with recurrent or progressive brain metastasesMedDRA version: 19.1Level: LLTClassification code 10025062Term: Lung cancer stage IVSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10006192Term: Breast cancer NOSSystem Organ Class: 100000004864MedDRA version: 19.1Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 100000004864EUCTR2013-005545-37-DEAIO-Studien-gGmbH
进行中（未招募）
不适用
Evaluation of cabazitaxel in patients with brain metastasis secondary to breast cancer and non-small-cell lung cancerBrain metastasis secondary to HER2-negative breast cancer and NSCLC, not previously irradiated and not requiring immediate radiation.MedDRA version: 16.0Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10059282Term: Metastases to central nervous systemSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005194-32-BEInstitut Jules Bordet
进行中（未招募）
1 期
A randomised study of cabazitaxel versus vinflunine in bladder carcinoma.metastatic or locally advanced transitional cell carcinoma of the urotheliumMedDRA version: 14.1Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10005084Term: Bladder transitional cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002826-55-ESAssociació Per a la Recerca Oncològica (APRO)70
招募中
不适用
A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urotheliumUrothelial Cancer1003836410046400Bladder CancerNL-OMON38902Associació Per a la Recerca Oncològica (APRO)50